Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics

Abstract

Summary Evidence‐based guidelines, or recommendations, for the management of infants with seizures are lacking. A Task Force of the Commission of Pediatrics developed a consensus document addressing diagnostic markers, management interventions, and outcome measures for infants with seizures. Levels of evidence to support recommendations and statements were assessed using the American Academy of Neurology Guidelines and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The report contains recommendations for different levels of care, noting which would be regarded as standard care, compared to optimal care, or “state of the art” interventions. The incidence of epilepsy in the infantile period is the highest of all age groups (strong evidence), with epileptic spasms the largest single subgroup and, in the first 2 years of life, febrile seizures are the most commonly occurring seizures. Acute intervention at the time of a febrile seizure does not alter the risk for subsequent epilepsy (class 1 evidence). The use of antipyretic agents does not alter the recurrence rate (class 1 evidence), and there is no evidence to support initiation of regular antiepileptic drugs for simple febrile seizures (class 1 evidence). Infants with abnormal movements whose routine electroencephalography (EEG) study is not diagnostic, would benefit from video‐EEG analysis, or home video to capture events (expert opinion, level U recommendation). Neuroimaging is recommended at all levels of care for infants presenting with epilepsy, with magnetic resonance imaging (MRI) recommended as the standard investigation at tertiary level (level A recommendation). Genetic screening should not be undertaken at primary or secondary level care (expert opinion). Standard care should permit genetic counseling by trained personal at all levels of care (expert opinion). Genetic evaluation for Dravet syndrome, and other infantile‐onset epileptic encephalopathies, should be available in tertiary care (weak evidence, level C recommendation). Patients should be referred from primary or secondary to tertiary level care after failure of one antiepileptic drug (standard care) and optimal care equates to referral of all infants after presentation with a seizure (expert opinion, level U evidence). Infants with recurrent seizures warrant urgent assessment for initiation of antiepileptic drugs (expert opinion, level U recommendation). Infantile encephalopathies should have rapid introduction and increment of antiepileptic drug dosage (expert opinion, level U recommendation). There is no high level evidence to support any particular current agents for use in infants with seizures. For focal seizures, levetiracetam is effective (strong evidence); for generalized seizures, weak evidence supports levetiracetam, valproate, lamotrigine, topiramate, and clobazam; for Dravet syndrome, strong evidence supports that stiripentol is effective (in combination with valproate and clobazam), whereas weak evidence supports that topiramate, zonisamide,...

The clinical profile and outcome of children with West syndrome in KwaZulu-Natal Province, South Africa: A 10-year retrospective review

“…[2] The overall response rate in our study was in keeping with other studies [2,9] that recommended the use of ACTH and prednisone for treatment of spasms in WS. The patient who did not respond to prednisone had focal cortical dysplasia on MRI.…”

“…[6] Significant contributing factors to the poor prognosis are the lack of standardised treatment guidelines, and delays in commencing treatment. This was evident after the results of studies from the Pellock et al, [2] Lux et al, [7] Ito et al, [8] and Wilmshurst et al [9] highlighted the treatment gap for WS. It was noted that further research was needed to formulate appropriate treatment protocols for WS with respect to pharmacological and non-pharmacological therapies, such as the ketogenic diet and neurosurgical interventions, such as vagal nerve stimulation, deep brain stimulation and epileptic surgery.…”

Surgical advancements in pediatric epilepsy surgery: from the mysterious to the minimally invasive

“…More than 50 million people worldwide have epilepsy, making it the most prevalent serious chronic neurological disorder. Seizures disproportionately affect children: the incidence is higher in infancy compared with any other age group (1,2).…”

Accuracy of Conventional Diagnostic Methods for Identifying Structural Changes in Patients with Focal Epilepsy

“…First generation computed tomography reveals only 3% of operable lesions (6). MRI, however, detects up to 80% of operable temporal lesions in patients who can benefit from a temporal lobotomy and up to 60% of frontal lesions in patients that can benefit from surgery of the frontal lobes (7,8 International League Against Epilepsy recommends performing an MRI in all patients with epilepsy, except for those with idiopathic generalized epilepsy (9). Crises originating from the back of the parietal lobe are most often clinically silent until they spread in the primary sensitive cortex or on other lobes, including frontal, temporal, or occipital (fi rst of all, the temporal region and motor frontal supplementary region) (10).…”